HR 3812 · 116th Congress · Health

REMEDY Act

Introduced 2019-07-17· Sponsored by Rep. McKinley, David B. [R-WV-1]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the Subcommittee on Health.(2019-07-18)

Plain Language Summary

[AI summary unavailable — showing source text] Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act This bill addresses drug patents with respect to Food and Drug Administration (FDA) approval of a drug application. Currently, when the owner of a brand-name drug approval sues a generic drug company for patent infringement based on the generic company's application for FDA approval of a generic version of the brand-name drug, there is generally a 30-month stay on the approval of the generic version. Under this bill, the stay goes into effect only if the lawsuit alleges infringement of a patent that claims the drug compound. When the U.S. Patent and Trademark Office invalidates a patent for a drug, the FDA must update its list of relevant patents for the drug.…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (1)

1 Democrat